Related Experiment Video

Updated: Oct 20, 2026

An Adoptive Transfer Model of Rheumatoid Arthritis in Mice
07:37

An Adoptive Transfer Model of Rheumatoid Arthritis in Mice

Published on: June 6, 2025

Vaccine strategies to prevent rheumatic fever

E R Brandt1, M F Good

  • 1Molecular Immunology Laboratory, The Co-operative Centre for Vaccine Technology, Queensland Institute of Medical Research. michaelG@qimr.edu.au

Immunologic Research
|June 22, 1999
PubMed

Insights

Developing a Group A Streptococcus (GAS) vaccine faces challenges due to M protein diversity and autoimmune risks. This review explores alternative GAS antigens as promising vaccine candidates to overcome these limitations.

Area of Science:

  • Microbiology
  • Immunology
  • Vaccinology

Background:

  • Group A Streptococcus (GAS) causes diverse human illnesses, from pharyngitis to severe invasive diseases and postinfectious sequelae like acute rheumatic fever.
  • Current vaccine development efforts primarily target the M protein, a major GAS virulence factor.
  • Limitations of M protein-based vaccines include extensive serotype variability and potential for autoimmune adverse reactions.

Purpose of the Study:

  • To review recent strategies for developing an effective Group A Streptococcus (GAS) vaccine.
  • To discuss the challenges associated with M protein-based vaccine approaches.
  • To explore alternative GAS antigens with protective properties as potential vaccine candidates.

Main Methods:

  • Literature review of recent studies on GAS vaccine development.
  • Analysis of M protein-based vaccine strategies and their limitations.
  • Identification and evaluation of other GAS antigens investigated for vaccine potential.

Main Results:

  • M protein-based vaccine development is hindered by numerous serotypes and risks of autoimmune responses.
  • Alternative streptococcal antigens are being investigated for their immunogenic and protective capabilities.
  • Emerging research highlights other GAS components as viable vaccine targets.

Conclusions:

  • Overcoming M protein-related vaccine challenges is crucial for effective GAS prevention.
  • Exploring alternative antigens offers a promising path towards a broadly protective GAS vaccine.
  • Further research into novel GAS vaccine candidates is warranted to address the global burden of streptococcal infections.

Related Concept Videos

Rheumatic Heart Disease III: Medical Management01:21

Rheumatic Heart Disease III: Medical Management

Rheumatic heart disease (RHD) management can be divided into two main strategies: prevention and long-term management.Primary PreventionPrimary prevention focuses on timely diagnosis and management of group A streptococcal pharyngitis to prevent acute rheumatic fever. The most widely used antibiotic for treating this condition is intramuscular benzathine penicillin G.Acute Rheumatic Fever TreatmentThe primary treatment goal for a patient diagnosed with acute rheumatic fever is to suppress the...
Respiratory Syncytial Virus Disease01:29

Respiratory Syncytial Virus Disease

Human respiratory syncytial virus (RSV) is a widespread pathogen that primarily targets infants and young children but also poses a serious health risk to elderly and immunocompromised individuals. Belonging to the Pneumoviridae family, RSV is a negative-sense, single-stranded RNA virus within the Pneumovirus genus. Its global health burden is significant, with millions of cases annually resulting in hospitalizations and mortality, particularly in resource-limited settings. Although most...
Rheumatic Heart Disease I: Introduction01:23

Rheumatic Heart Disease I: Introduction

Rheumatic heart disease or RHD is a chronic condition that results from rheumatic fever, causing permanent damage to the heart valves.Etiology and Risk FactorsIt primarily arises from rheumatic fever, an inflammatory disease that can develop after untreated or inadequately treated group A streptococcal (GAS) pharyngitis. Streptococcus spreads through direct contact with oral or respiratory secretions. While the bacteria are the causative agents, factors like malnutrition, overcrowding, poor...
Rheumatic Heart Disease IV: Nursing Management01:20

Rheumatic Heart Disease IV: Nursing Management

AssessmentA comprehensive assessment is essential in managing a patient with rheumatic heart disease (RHD). Begin with obtaining a detailed medical history, including recent streptococcal infections, a history of rheumatic fever, or previously diagnosed rheumatic heart disease. Assess the patient for symptoms such as fever, chest pain, widespread joint pain (arthralgia), tachycardia, pericardial friction rub, muffled heart sounds, heart murmurs, peripheral edema, subcutaneous nodules, and...
Streptococcal Pharyngitis01:27

Streptococcal Pharyngitis

Streptococcal pharyngitis, commonly known as “strep throat,” is an acute infection of the oropharyngeal tissues caused by the Gram‑positive Group A Streptococcus (Streptococcus pyogenes). Transmission occurs primarily through respiratory droplets expelled during coughing, sneezing, or talking.Mechanisms of Host Entry and Immune EvasionUpon entering the host, S. pyogenes adheres to the mucosal epithelial cells of the pharynx via surface proteins, notably lipoteichoic acid and the antiphagocytic...
Mitral Stenosis III: Medical Management01:26

Mitral Stenosis III: Medical Management

Mitral stenosis, a condition marked by the narrowing of the mitral valve, necessitates an integrated approach for effective management. This approach includes preventative measures, medical therapy, and surgical interventions to reduce symptoms and prevent complications.PreventionPrevention of mitral stenosis primarily focuses on reducing the incidence of bacterial infections, particularly streptococcal infections, which can lead to rheumatic fever and subsequent valvular damage. Timely...